The invention relates to 3apos; , 4apos; preparation method of plant extract of, 5, 7-tetrahydroxyflavone and derivative thereof and application of plant extract to reduction of uric acid
By extracting luteolin and its derivatives from plants and using its xanthine oxidase inhibitory activity, the problem of existing gout treatment methods on kidney and liver function damage is solved, and safe and effective uric acid reduction and renal protection effects are achieved.
Patent Information
- Application Number
- CN202411210516.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-06
AI Technical Summary
The existing gout treatment methods have major side effects, especially potential damage to renal and liver function, and lack safe and economical uric acid-reducing drugs.
A plant was prepared by extracting luteolin and its derivatives from plants rich in 3',4',5,7-tetrahydroxyflavonoids and their derivatives, and reducing uric acid levels by using its xanthine oxidase inhibitory activity to reduce uric acid levels, a plant was prepared Extracts are used to prevent and treat hyperuricemia.
This extract can significantly reduce the uric acid level in the serum and liver, reduce kidney damage caused by high uric acid, and has no obvious toxic side effects, is accurate in efficacy, is safe and controllable, and is low in price. It is suitable for the preparation of drugs and foods for lowering uric acid.
Smart Images

Figure CN119080728A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of natural drug chemistry and food and medicine technology, and specifically relates to a preparation method of a plant extract of 3',4',5,7-tetrahydroxyflavone and its derivatives and an application thereof in lowering uric acid. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
[0003] Hyperuricemia (commonly known as gout) is an inflammatory disease with recurrent attacks caused by increased purine anabolism in the body, excessive uric acid production or increased uric acid in the blood due to poor uric acid excretion, and deposition of urate crystals in the synovium, bursa, cartilage and other tissues. It is a group of heterogeneous diseases caused by the deposition of monosodium urate crystals (MSU) or uric acid in the extracellular fluid to form a supersaturated state, causing its crystals to deposit in the tissue. Gout patients are usually accompanied by arthritis, tophi, gouty nephropathy and uric acid urinary stones. At the same time, gout can cause vascular sclerosis and increase the complications of cardiovascular and cerebrovascular diseases.
[0004] Hyperuricemia (gout) is distributed all over the world and is affected by many factors such as race, diet, drinking, occupation, environment and education level. The prevalence of gout in Europe and the United States is 0.2%-1.7%. In recent years, the incidence of gout in China has been on the rise, and the prevalence in the general population is about 1.14%. With the rising trend of hyperuricemia, hyperuricemia has also become the fourth highest risk of potential chronic diseases, and April 20th of each year is designated as World Gout Day. Currently, the commonly used treatments for hyperuricemia (gout) include surgical treatment, such as resection of gouty nodules that affect functional activities and systemic treatment; drug treatments such as colchicine (0.6 mg / h, until gastrointestinal side effects (such as nausea, vomiting or diarrhea) occur or a maximum of 6 to 8 doses in total) (BN Cronstein and R. Terkeltaub, The inflammatory process of gout and its treatment), indomethacin (100 μg / d, 2 to 3 days) and febuxostat (oral tablets), etc. So far, both surgical and drug treatments have significant side effects, especially potential damage to kidney and liver function.
[0005] In recent years, studies have found that flavonoids and flavonoid compounds contained in various plant extracts, such as celery seeds, honeysuckle and chrysanthemum, have the effect of reducing uric acid and relieving hyperuricemia (gout). Long-term use of effective extracts can reduce uric acid levels and relieve gout, and has obvious effects in preventing and treating hyperuricemia. Compared with surgical treatment and drug treatment, long-term use of celery seed extract has higher safety, and also greatly reduces the concerns and economic burden of drug treatment that may cause liver and kidney damage. As people's research on natural products and traditional Chinese medicine ingredients becomes more and more in-depth, it is found that flavonoids and flavonoid compounds rich in natural organisms have been proven to have medicinal value.
[0006] 3′,4′,5,7-tetrahydroxyflavone, also known as luteolin, is a natural flavonoid compound that exists in a variety of plants in the form of glycosides. Among them, celery seeds, wild chrysanthemums, honeysuckle, perilla and peanut shells have higher content. Luteolin and its derivatives have significant anti-inflammatory and antioxidant activities. Studies have shown that luteolin and its derivatives have multiple effects such as anti-inflammatory, anti-tumor, anti-fibrosis, antioxidant, anti-microbial, anti-diabetic, neuroprotective and anti-allergic, and also have the function of regulating chronic inflammation. In addition, many studies have shown that luteolin and its derivatives have significant xanthine oxidase inhibitory activity and can significantly reduce serum uric acid in hyperuricemia model mice and rats. Summary of the invention
[0007] In view of the above-mentioned prior art, the purpose of the present invention is to provide a method for preparing 3′, 4′, 5, 7-tetrahydroxyflavonoids and their derivatives plant extracts and their application in lowering uric acid. Specifically, the present invention uses plants rich in 3′, 4′, 5, 7-tetrahydroxyflavonoids and / or their derivatives as raw materials, and screens out highly active luteolin and / or its derivatives extracts through a simple and easy method. Experiments have shown that the extracts can reverse the increase in xanthine oxidase activity caused by potassium oxonate, causing uric acid synthesis to be blocked, thereby reducing uric acid, blood urea nitrogen levels and serum creatinine in serum and liver. Based on the above research results, the present invention is completed.
[0008] Specifically, the technical solution of the present invention is as follows:
[0009] In a first aspect of the present invention, a plant extract of 3',4',5,7-tetrahydroxyflavone and its derivatives is provided, wherein luteolin and / or its derivatives have a high abundance in the plant extract; the luteolin and / or its derivatives include but are not limited to luteolin, luteolin glycoside, luteolin-7-O-rutinoside, luteolin-6-C-glucoside and luteolin disaccharide, etc.
[0010] The plants include any one or more of honeysuckle, chrysanthemum, peanut shells, pepper leaves, astragalus, celery seeds, celery, schizonepeta, white-haired selfhen, and artichoke; further, the plants are any one or more of peanut shells, honeysuckle, chrysanthemum, celery seeds, or pepper leaves; further, they are any one or more of peanut shells, celery seeds, and pepper leaves.
[0011] It has been verified that the above-mentioned luteolin-rich plant extract is useful in preventing, treating or improving hyperuricemia, and has a significant positive correlation with the combination of the above-mentioned luteolin and / or its derivative monomer components.
[0012] In the second aspect of the present invention, there is provided a method for preparing the plant extract of 3',4',5,7-tetrahydroxyflavone and its derivatives as described in the first aspect, comprising the following steps:
[0013] S1. After drying, crushing and sieving the plants, a low-polarity organic reagent is added for degreasing; the defatted plants are air-dried for later use;
[0014] S2, transferring the dried defatted plant powder into an alcohol solution for extraction, combining the extracts and drying to obtain an extract;
[0015] S3. Dissolve the extract with ethanol, and pass it through a silica gel column and / or a macroporous resin column and / or a polyamide column to obtain a flavonoid extract rich in luteolin and / or its derivatives.
[0016] Wherein, in step S1, the low-polarity organic reagent is any one of petroleum ether, n-hexane, dichloromethane, ethyl acetate, and ether, or a combination of two reagents; further preferably, the low-polarity organic reagent is n-hexane and / or ethyl acetate.
[0017] The defatting treatment steps are as follows: adding a low-grade organic reagent to the crushed plant and extracting at room temperature for 3-5 times, adding 3-5 times the volume of the plant powder each time, the total extraction time is 3-5 hours, filtering and retaining the solid powder in the reflux system to obtain the defatted plant powder;
[0018] In step S2, the alcohol solution is methanol, ethanol or a mixed solution of ethanol and water; in a further preferred embodiment, the alcohol solution is ethanol; further, the specific steps of preparing the extract are as follows: adding 10-20 times the volume of ethanol to the defatted plant powder, reflux extraction at 25-80°C for 3-5 times, each reflux extraction time is 1.5-48 hours, and the combined extracts are dried by vacuum concentration.
[0019] The present invention screens and studies the monomer active ingredients in the plant extracts rich in luteolin and / or its derivatives, and screens the following monomer components from honeysuckle, chrysanthemum, peanut shell, pepper leaf, astragalus, celery seed or celery, etc., which have good effects of inhibiting xanthine oxidase activity, reducing serum uric acid levels, and preventing, treating or improving hyperuricemia: luteolin, luteolin glycoside, luteolin-7-O-rutinoside, luteolin-6-C-glucoside and luteolin disaccharide, etc.
[0020] Therefore, the third aspect of the present invention provides the use of the above-mentioned 3',4',5,7-tetrahydroxyflavone and its derivative plant extracts and flavonoid monomer compounds in the preparation of products for preventing and / or treating hyperuricemia.
[0021] Specifically, the prevention and / or treatment of hyperuricemia is achieved by lowering serum urea, creatinine and urea nitrogen levels and reversing kidney damage caused by hyperuricemia. Furthermore, reversing kidney damage caused by hyperuricemia includes reversing the increased xanthine oxidase activity caused by hyperuricemia and reversing the 24-hour urine, total protein, microalbumin excretion caused by hyperuricemia.
[0022] In another specific embodiment of the present invention, the flavonoid monomer compound is any one or more of luteolin, luteolin glycoside, luteolin-7-O-rutinoside, luteolin-6-C-glucoside and luteolin disaccharide.
[0023] The products include but are not limited to food, medicine and daily chemical products.
[0024] It should be noted that, in the present invention, the term "food" used should be understood in a broad sense, and it can be understood as any form that can be eaten. For example, the food in the present invention includes ordinary food and special food. The special food in the present invention includes health food and special medical formula food; it prevents, alleviates or assists in the treatment of related diseases such as hyperuricemia.
[0025] Ordinary food is relative to special food and is food suitable for everyone.
[0026] The food includes but is not limited to solid food and liquid food; the solid food includes but is not limited to baked food (such as biscuits, bread, cakes), candy, solid beverages, etc.; the liquid food includes but is not limited to liquid beverages (such as carbonated beverages, fruit juice beverages, milk beverages), etc.
[0027] In the drug, the active dose of the plant extract of 3',4',5,7-tetrahydroxyflavonoids and its derivatives can be routinely determined according to factors such as the subject and the method of use; calculated based on the total mass of the drug, the dose of the plant extract of 3',4',5,7-tetrahydroxyflavonoids and its derivatives is adjusted within the range of 0.01 to 99%, and further, it can be 0.01 to 0.05%, 0.05 to 0.1%, 0.1 to 0.3%, 0.3 to 0.5%, 0.5 to 1%, 1 to 3%, 3 to 5%, 5 to 10%, 10 to 20%, 20 to 30%, 30 to 50%, 50 to 70% or more. 70-99%; in addition, the drug can select the corresponding preparation type according to the purpose of administration, metabolic performance, etc., including but not limited to tablets, capsules, granules, pills, oral liquids, suspensions and injections; of course, the drug can also include a pharmaceutically acceptable carrier in the art, which should be harmless to the subject and even sterile, including but not limited to buffers, antioxidants, preservatives, bactericides, proteins, hydrophilic polymers, amino acids, monosaccharides, disaccharides and other carbohydrates, chelating agents, tension regulators, sugars, surfactants, salt-forming counterions, metal complexes and / or non-ionic surfactants.
[0028] The daily chemical products can be laundry detergents, personal hygiene cleansers and cosmetics (which can further be skin care products), etc., specifically toothpaste, mouthwash, clothing disinfectant, shampoo, hair lotion, hair spray, shower gel, soap, facial mask, facial cream, facial cleanser, etc.
[0029] The beneficial effects of one or more of the above technical solutions are:
[0030] The above technical scheme uses plants rich in luteolin and / or its derivatives as raw materials, and screens out highly active luteolin and / or its derivatives extracts therefrom in a simple and easy manner. The extracts contain a relatively high content of highly active luteolin and / or its derivatives monomers, which can reverse the increased xanthine oxidase activity caused by potassium oxonate, causing the inhibition of uric acid synthesis, thereby reducing the levels of uric acid, blood urea nitrogen and serum creatinine in serum and liver.
[0031] The above technical scheme also determines that plant extracts rich in luteolin and / or its derivatives and their monomer compounds can reduce kidney swelling caused by hyperuricemia, reverse kidney damage caused by hyperuric acid, have kidney protection function, and do not damage the liver, have no obvious toxic side effects, have definite efficacy, are safe and controllable, and are inexpensive. They can be used to prepare drugs, foods, and daily chemical products for preventing, treating, or improving hyperuricemia and kidney damage caused by hyperuric acid, and therefore have good practical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.
[0033] Figure 1 is the general structural formula of the monomers of luteolin and its derivatives related to the present invention;
[0034] Figure 2 The hydrogen spectrum of luteolin of the present invention;
[0035] Figure 3 This is the carbon spectrum of luteolin of the present invention;
[0036] Figure 4 The hydrogen spectrum of luteolin disaccharide glycoside of the present invention;
[0037] Figure 5 This is the carbon spectrum of luteolin disaccharide glycoside of the present invention;
[0038] Figure 6 This is the HPLC spectrum of the luteolin derivative of the celery seed extract of the present invention;
[0039] Figure 7 The figure is the HPLC spectrum of luteolin from peanut shell extract of the present invention. DETAILED DESCRIPTION
[0040] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used in the present application have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.
[0041] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.
[0042] The present invention is further explained below by way of examples, but is not intended to limit the present invention.
[0043] Example 1
[0044] In this embodiment, a plant extract rich in luteolin and / or its derivatives is provided, taking peanut shells, celery seeds and pepper leaves as examples, and the preparation method of the extract is as follows:
[0045] Dry the plant to a constant weight at 50°C, then crush it using a grinder, pass it through a 60-mesh sieve, and obtain fine powder. Take 50g of plant fine powder and soak it in 150ml of n-hexane, and filter it after 5h. Repeat the extraction three times. Dry the filter residue for later use. Weigh 50g of the dried plant fine powder filter residue and soak it in 600ml of ethanol, stir and extract at room temperature for 12h. Repeat the extraction 3 times, and the extract is concentrated under reduced pressure to obtain a plant extract, the content of luteolin and its derivatives is not less than 30%.
[0046] The peanut shell extract was mixed with 1.5 times the weight of silica gel and loaded with 50 times the weight of silica gel. Different ratios of methanol / dichloromethane (MeOH / DCM=0-10%) were used for gradient elution, and the luteolin mixture fraction was collected by TLC and HPLC detection. Subsequently, the luteolin mixture fraction was continuously eluted with MeOH / DCM gradient (MeOH / DCM=0-10%) to obtain the compound luteolin.
[0047] After obtaining the celery seed extract, dissolve it in 1.5 times the weight of methanol, apply it to a macroporous resin column (D101), use water and methanol as elution solvents for gradient elution, the volume ratio of methanol-water = 1%, 5%, 10%, 30%, 50%, 70%, 90% and 100%, collect the flavonoid glycoside fractions according to the TLC and HPLC test results, and concentrate under reduced pressure to obtain a flavonoid glycoside mixture. Subsequently, use a preparative liquid phase to separate the flavonoid glycosides. Collect the target components, and concentrate under reduced pressure to obtain luteolin and luteolin disaccharide glycosides.
[0048] After obtaining the pepper leaf extract, dissolve it in methanol with 1.5 times its weight, apply it to a macroporous resin column (D101), use water and methanol as elution solvents for gradient elution, the volume ratio of methanol-water = 1%, 5%, 10%, 30%, 50%, 70%, 90% and 100%, collect the flavonoid glycoside fraction according to the TLC and HPLC test results, and concentrate under reduced pressure to obtain a flavonoid glycoside mixture. Subsequently, use a preparative liquid phase to separate the flavonoid glycosides. Collect the target component, and concentrate under reduced pressure to obtain luteolin-7-O-rutinoside and luteolin-6-C-glucoside.
[0049] Characterization of uric acid lowering effect
[0050] In the following examples, the urine of mice was collected to detect the urine output, and the kit was used to detect the levels of serum uric acid, urea nitrogen, creatinine, total protein in urine, and microalbumin in urine (MUA); HE staining and immunohistochemistry were used to observe the pathological changes in the liver and kidney, and to detect whether luteolin could improve the renal damage of hyperuricemia mice; the kit was used to detect the renal function indicators and renal damage indicators of hyperuricemia mice.
[0051] Example 2
[0052] Hyperuricemia model in mice induced by potassium salt of para-oxonate: After continuous administration for 7 days, the mice were intraperitoneally injected with potassium salt of para-oxonate to cause hyperuricemia in the mice, and the serum UA of the mice increased.
[0053] Administration for hyperuricemia: Effects of plant extracts rich in luteolin and its derivatives and their monomers on the mouse hyperuricemia model induced by potassium salt of oxonic acid: 55 ICR mice, SPF male, weighing 24.1-27.9g, were randomly divided into 11 groups according to body weight, namely A: normal control group; B: model control group; C: allopurinol group; D: luteolin group; E: luteolin glycoside group; F: luteolin disaccharide group; G: peanut shell extract group; H: celery seed extract group; I: pepper leaf extract group; luteolin group, luteolin glycoside group, luteolin disaccharide group and peanut shell, celery seed and pepper leaf extract group (5g / kg), 5 animals in each group. Group C was given allopurinol 2.4mg / 100g; Groups D, E, and F were given luteolin, luteolin glycosides, and luteolin disaccharide 50mg / kg, respectively; Groups G, H, and I were given peanut shell, celery seed, and pepper leaf extract 5g / kg, respectively. Each group of mice was given the corresponding dose of drug solution by gavage at 20mL / kg, the normal control group was given an equal volume of distilled water by gavage, and the model control group was given an equal volume of peanut oil by gavage, once a day, for 7 consecutive days. Before the last administration, the mice were fasted but not watered for 12h. One hour before administration, except for the normal control group, the mice in the other groups were intraperitoneally injected with 300mg / kg of potassium salt of oxonate. Before modeling and 1h after the last administration, the eyeballs of the mice in each group were removed to collect blood, centrifuged at 4000rpm, 4℃ for 10min, and the supernatant was used to detect serum uric acid, creatinine, urea nitrogen levels and xanthine oxidase activity. After blood collection, mice were killed by cervical dislocation, and cardiac perfusion was performed with pre-cooled saline to remove blood from the liver and kidneys. Two small pieces of liver were taken on ice, one of which was quickly placed in an EP tube in an ice bath for the preparation of liver tissue homogenate. The other piece of liver was fixed in 4% paraformaldehyde solution for the observation of liver pathological changes. Both kidneys were removed, photographed and weighed, and the kidney index was calculated. The kidney index calculation formula is as follows: kidney index (%) = weight of both kidneys (g) * 100 / body weight (g).
[0054] The kidney was cut into two parts longitudinally and placed in 2 mL labeled EP tubes, one part was stored in a -80℃ refrigerator, and the other part was stored in liquid nitrogen. All operations were performed on ice. The above groups were gavaged, intraperitoneally injected with normal saline, and administered at 0.4 mL / 20 g. The results are shown in Tables 1-3.
[0055] Table 1 Effects of plant extracts rich in luteolin and its derivatives and its monomer potassium oxazine on serum uric acid, creatinine and urea nitrogen levels in hyperuricemic mice
[0056]
[0057]
[0058] A is 0-60; B is 60-90; C is 90-120; D>120. W is 0-10; X is 10-15; Y is 15-20; Z>20.
[0059] The three extracts and three flavonoid monomers can significantly reduce the levels of serum uric acid, serum creatinine and urea nitrogen in HUA mice
[0060] Table 1 shows the effects of three extracts and three flavonoid monomers on blood uric acid in hyperuricemia model mice. It can be seen from the table that compared with the control group, the serum uric acid level of the model group mice was statistically significant, indicating that the model was successful. Compared with the model group, the allopurinol group can reduce the levels of serum uric acid, serum creatinine and urea nitrogen in HUA mice. Peanut shell extract, celery seed extract and pepper leaf extract can all reduce the levels of serum uric acid, creatinine and urea nitrogen in HUA mice, and the flavonoid components in the three extracts play a major role. In addition, the luteolin glycoside compound reduces serum uric acid, creatinine and urea nitrogen levels more than its aglycone luteolin, and its effect increases with the increase of sugar units.
[0061] The three extracts and three flavonoid monomers can reduce the uric acid level, blood urea nitrogen level and serum creatinine in hyperuricemia mice, and alleviate kidney damage caused by hyperuricemia and hyperuric acid.
[0062] Table 2 Effects of plant extracts rich in luteolin and its derivatives and its monomer potassium oxazine on renal index, serum and liver xanthine oxidase activity in hyperuricemia mice
[0063]
[0064]
[0065] SXOD: kidney xanthine oxidase activity; LXOD: liver xanthine oxidase activity. A is 0-10; B is 10-15; C is 15-20; D>20. W is 0-5; X is 5-7; Y is 7-9; Z>9. Q is 0-1.5; R is 1.5-2; S is 2-2.5; T>2.5.
[0066] Three extracts and three flavonoid monomers can reverse the increase in xanthine oxidase activity caused by hyperuricemia
[0067] As shown in Table 2, compared with the model control group, the serum and liver xanthine oxidase activities of the allopurinol and drug-treated groups were statistically significant. Consistent with the results of lowering uric acid, peanut shell extract, celery seed extract and pepper leaf extract were able to reverse the increase in xanthine oxidase activity caused by hyperuricemia, and the flavonoid components in the three extracts played a major role. In addition, the luteolin glycoside compound reversed the increase in xanthine oxidase activity caused by hyperuricemia more than its aglycone luteolin, and its effect increased with the increase of sugar units. The three extracts and three flavonoid monomers can reduce the renal index of hyperuricemia mice, indicating that they can reduce hyperuricemia and renal damage caused by hyperuricemia.
[0068] Example 3 Detection of urine total protein and urine microalbumin in the urine obtained in Example 2
[0069] The urine collected in Example 2 was centrifuged at 16000g and 4°C for 10 min, and the supernatant was taken. The mouse urine microalbumin was tested according to the requirements of the above-mentioned mouse urine microalbumin (MAU) ELISA kit. The mouse urine total protein concentration was tested according to the requirements of the above-mentioned BCA kit. The 24 total protein and microalbumin excretion were then calculated based on the 24h urine excretion.
[0070] Table 3 Effects of plant extracts rich in luteolin and its derivatives and their monomers on urine total protein and urine microalbumin in mice with hyperuricemia induced by potassium oxazine
[0071]
[0072]
[0073] A is 0-5; B is 5-10; C is 10-15; D>15.
[0074] Three extracts and three flavonoid monomers can alleviate kidney damage caused by hyperuric acid in mice
[0075] As shown in Table 3, compared with the control group, the model group had significantly increased 24h urine, total protein, and microalbumin excretion. The three extracts and three flavonoid monomer groups were able to reverse the significantly increased 24h urine, total protein, and microalbumin excretion caused by hyperuricemia. The results showed that the three extracts and three flavonoid monomers could prevent, treat, or improve hyperuricemia and renal damage caused by hyperuricemia. Moreover, the three extracts and three flavonoid monomers are pure plant extracts or their active ingredients, which have the advantages of small toxic and side effects, definite efficacy, safety and controllability, and low price. The three extracts and three flavonoid monomers can be developed into new drugs and health products for lowering uric acid and improving hyperuricemia renal damage, which have good application prospects.
[0076] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A plant extract of 3',4',5,7-tetrahydroxyflavonoids and its derivatives, characterized in that: The plant extract has a high abundance of luteolin and / or its derivatives; the luteolin and / or its derivatives include luteolin, luteolin glycoside, luteolin-7-O-rutinoside, luteolin-6-C-glucoside and luteolin disaccharide.
2. The plant extract according to claim 1, characterized in that The plants include any one or more of honeysuckle, chrysanthemum, peanut shells, pepper leaves, astragalus, celery seeds, celery, schizonepeta, white-haired selfhen, and artichoke; further, the plants are any one or more of peanut shells, honeysuckle, chrysanthemum, celery seeds, or pepper leaves; further, they are any one or more of peanut shells, celery seeds, and pepper leaves.
3. The method for preparing the plant extract of 3',4',5,7-tetrahydroxyflavonoids and its derivatives according to claim 1 or 2, characterized in that: The steps include: S1. After drying, crushing and sieving the plants, a low-polarity organic reagent is added for degreasing; the defatted plants are air-dried for later use; S2, transferring the dried defatted plant powder into an alcohol solution for extraction, combining the extracts and drying to obtain an extract; S3. Dissolve the extract with ethanol, and pass it through a silica gel column and / or a macroporous resin column and / or a polyamide column to obtain a flavonoid extract rich in luteolin and / or its derivatives.
4. The preparation method according to claim 3, characterized in that: In step S1, the low-polarity organic reagent is any one of petroleum ether, n-hexane, dichloromethane, ethyl acetate, and ether, or a combination of two of the reagents; further preferably, the low-polarity organic reagent is n-hexane and / or ethyl acetate.
5. The preparation method according to claim 3, characterized in that: In step S1, the defatting treatment is as follows: add low-grade organic reagents to the crushed plants and extract them 3-5 times at room temperature, adding 3-5 times the volume of the organic reagent of the plant powder each time, and the total extraction time is 3-5 hours. The solid powder retained in the reflux system is the defatted plant powder.
6. The preparation method according to claim 3, characterized in that: In step S2, the alcohol solution is methanol, ethanol or a mixed solution of ethanol and water; further, the alcohol solution is ethanol; further, the specific steps of preparing the extract are as follows: add 10-20 times the volume of ethanol to the defatted plant powder, reflux extract at 25-80°C for 3-5 times, each reflux extraction time is 1.5-48 hours, and the combined extracts are dried by reduced pressure concentration.
7. Use of the plant extract of 3',4',5,7-tetrahydroxyflavone and its derivatives and flavonoid monomer compounds according to any one of claims 1 to 2 in the preparation of products for preventing and / or treating hyperuricemia.
8. As used in claim 7, characterized in that The prevention and / or treatment of hyperuricemia is achieved by lowering serum urea, creatinine and urea nitrogen levels and reversing kidney damage caused by hyperuricemia. Furthermore, reversing kidney damage caused by hyperuricemia includes reversing the increased xanthine oxidase activity caused by hyperuricemia and reversing the 24-hour urine, total protein and microalbumin excretion caused by hyperuricemia.
9. The use according to claim 7, characterized in that: The flavonoid monomer compound is any one or more of luteolin, luteolin, luteolin glycoside, luteolin-7-O-rutinoside, luteolin-6-C-glucoside and luteolin disaccharide.
10. The use according to claim 7, characterized in that: The products include food, medicine and daily chemical products.
Citation Information
Patent Citations
Application of flavonoids of celery seed and coumarins in preparation of drug for preventing and treating gout
CN101007015A
Application of celery seed extract to preparation of medicine or health-care food for resisting to hyperuricemia and gout
CN105535048A
Application of Graveobioside A in preparation of drugs or healthcare food for preventing hyperuricemia and gout
CN105560262A
Application of luteolin and derivatives thereof in medicines for preventing and treating hyperuricemia and improving kidney injury caused by hyperuricemia
CN111388465A
Celery seed extract as well as preparation method and application thereof
CN112716989A
